Articles tagged with Drug Delivery
Mount Sinai researchers collaborate with Johnson & Johnson to evaluate a liquid radioembolic agent for treating brain tumors. The agent combines radiation delivery and embolization to target tumors, offering a new approach for managing difficult-to-remove tumors.
MIT researchers developed a new technique to produce lipid nanoparticles with precise control over size and shape, accelerating the development of RNA and DNA therapeutics. The automated system can produce particles of varying sizes and shapes, enabling targeted delivery to specific organs and tissues.
Researchers at MIT have created tiny, bioresorbable batteries that can power ingestible electronic devices, such as RFID tags and capsules that stimulate ghrelin production, for up to three days. The batteries, made from magnesium and molybdenum trioxide, can be fully broken down and absorbed by the body, reducing environmental impact.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
Researchers are evaluating the health and economic consequences of subpar buprenorphine dosing among Medicaid-covered pregnant women to improve maternal and infant outcomes. Data suggest that up to 90% of pregnant women require higher doses of buprenorphine.
Researchers have developed a technology that combines aminoglycoside antibiotics with PKZ18 analogs, resulting in up to an 8-fold increase in efficacy and reduced risk of microbial resistance. This synergy enables targeting of bacteria in various environments, expanding the therapeutic window.
BioLife has developed a novel oral peptide delivery technology that uses a dissolvable effervescent tablet format to protect peptide medicines during digestion. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept.
Researchers developed asymmetric charged vesicles to improve drug entrapment and delivery. These vesicles allow for different charges on the inside and outside, maximizing drug loading and reducing side effects.
Researchers developed biodegradable particles with microscopic needles to improve skin absorption of drugs delivered through patches or creams. The technology increased intradermal drug delivery up to 37-fold for three different drugs.
Scientists developed laser-carved microvalves to protect fragile brain catheters from backflow, enabling smooth delivery of therapies. The valves regulate fluid flow through geometry without moving parts, suppressing reverse pressure surges by up to 82%.
Researchers developed a bio-based Fe-MOF nanoreactor that combines natural-ligand chemistry with multimetallic redox catalysis, biomimetic targeting and MRI visibility. The nanoplatform produced a strong ROS response, increased apoptosis, and tumor inhibition in breast cancer cells and mice.
NTU Singapore scientists have developed microdroplets that deliver large amounts of gene-silencing molecules into cancer and immune cells, reducing colorectal tumor growth by 67% in mice. The approach targets two proteins that cancer cells exploit to evade immune attacks, and could potentially cost 5-10 times less to produce than curre...
Researchers at IIT Gandhinagar develop a gold nanorod-based platform for ER-targeted cancer treatment, combining targeted drug delivery with photothermal therapy. The approach induces ER stress-mediated autophagy and apoptosis in cancer cells.
Researchers at Kumamoto University have created a mobile drug delivery platform using polyrotaxanes to simplify targeting the liver. The platform achieves cellular uptake efficiency comparable to conventional systems, while reducing manufacturing complexity.
Researchers from Pusan National University developed an injectable system to deliver radiation directly within keloid tissue, providing a minimally invasive approach to treat abnormal scars. The microgels enabled rapid and efficient radiolabeling, and therapeutic efficacy was demonstrated in mice carrying patient-derived keloid tissue.
Researchers emphasize the need for personalized drug delivery systems that consider tumor biology, location, and patient factors to effectively treat oral cancer. Mucoadhesive films, oral sprays, and injectable hydrogels are promising technologies, but their translation to clinical use depends on practical considerations.
Scientists create a new material that changes from a gel to a liquid-like state under ultraviolet light, and can be rebuilt using heat or dismantled by acid. The discovery could lead to the design of smart sensors, switchable catalysts, and materials that capture and release selected molecules on demand.
Researchers from Hebei Medical University review current evidence on prolonged disorders of consciousness (pDOC) management. They propose a brain communication network model to explain how brain injury leads to long-term unconsciousness, identifying key brain electrical signaling activity measures for diagnosis and treatment.
Recent research explores the use of nanomaterial-based drug delivery to increase treatment efficacy for glioblastoma, a type of brain tumor with poor prognosis. Stimuli-responsive and biomimetic nanomedicines are designed to overcome the blood–brain barrier and deliver drugs selectively within tumors.
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
A multidisciplinary team of Penn researchers has developed a platform that delivers a combination of cancer-fighting therapies to treat oral squamous cell carcinoma. The findings show that the platform significantly reduces tumor burden and extends survival in aggressive, p53-therapy-resistant cancer models.
Emerging non-endocytic delivery strategies enable direct cytosolic delivery of proteins, nucleic acids, and gene-editing tools, providing new opportunities for biomedical therapies. The review discusses their application prospects in gene therapy, macromolecular drug delivery, and cellular engineering.
Researchers develop novel extracellular vesicle platform that makes bacteria more susceptible to polymyxins, enabling lower and safer treatment doses. The platform was shown to enhance bacterial killing and cause minimal toxicity in murine models.
Tosyl groups act as a form of molecular code, enabling pseudorotaxane-like geometries and biased macrocyclization reactions. The number of tosyl units determines higher-order assembly behavior, including ring closure and polymeric chain formation.
Researchers developed a nanoparticle system that uses cancer cells' own copper resources to activate cuproptosis, eliminating tumor cells while protecting healthy tissue. The targeted nanoparticles showed enhanced cellular uptake and were more lethal to breast cancer cells than non-targeted versions.
Researchers developed nanoparticles that retain their protective coating in normal tissue but shed it upon reaching tumor tissue, releasing anticancer drugs. This technology reduces systemic side effects and enhances treatment efficacy.
Researchers developed a physics-informed neural network approach to predict material properties and optimize controlled-release systems. The new method requires significantly less data than traditional AI models, slashing development time for patches, bandages, and implants.
Researchers create tiny swimmers to deliver drugs through the human body, finding they reverse direction in non-Newtonian fluids like mucus and blood. This discovery enhances understanding of fluid behavior and could lead to targeted drug delivery.
Expanding heart failure care to pharmacists and nurse practitioner-led medication management can save approximately 10 lives and prevent 25 hospitalizations per 1,000 patients. This service is estimated to be cost-effective and improve patient outcomes, providing a roadmap for a stronger healthcare system.
Researchers developed a pH-triggered nanocomposite that synchronizes the release of therapeutic agents, combating bacterial biofilms and oxidative stress. The platform accelerates healing and promotes tissue repair in infected wounds.
Researchers developed mathematical models and simulations to predict the behavior of a unique drug-delivery method, aiming to reduce medication side effects while increasing treatment efficacy. The method uses magnetic particles to guide cell-like drug carriers toward specific targets in the body.
A recent study found that the FDA approval of semaglutide for weight management led to a significant increase in calls to poison control centers, with over 8,000 cases reported by 2023. The majority of errors were preventable and stemmed from unintentional dosing or therapeutic mistakes.
Researchers developed an injectable hydrogel combining silk proteins and a kudzu plant compound, achieving complete wound closure within 72 hours. The material's mechanical stability and cell viability exceeded expectations.
Researchers designed artificial proteins that simultaneously form pentagonal and hexagonal arrangements to create virus-like structures. These structures can stably carry drugs, genetic materials, and enzymes within their interior space.
Researchers at the University of Houston have discovered adding salt can help release therapeutic material from endosomes, improving delivery efficiency for mRNA vaccines and gene therapies. The simple strategy overcomes a major obstacle in gene medicine, potentially making these therapies more efficient and accessible worldwide.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Researchers create a hydrogel-based oral formulation that coats the esophageal lining and releases antibodies like infliximab to treat inflammatory conditions. The formulation reduces side effects by temporarily loosening cell-cell junctions, allowing larger molecules to pass through.
A recent study by Semmelweis University found that alkaline mineral and medicinal waters can weaken the enteric coating of medications, reducing their effectiveness. The study analyzed 22 beverages and found that tap water was less damaging to the coating than acidic or alkaline liquids.
MIT researchers have developed low-cost, 3D-printed triaxial electrospray emitters that efficiently produce three-layered particles at scale. The devices can be used to manufacture time-release drug-delivery nanoparticles with potential applications in biosensors and tissue regeneration.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
Researchers developed anisotropy-tunable mesoporous polydopamine nanomotors with POM-mediated assembly, which combine intrinsic antibacterial activity, self-propulsion, and high drug-loading capacity. These nanomotors demonstrate enhanced antibacterial efficiency and biofilm eradication against drug-resistant bacterial biofilms.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
The study uses DNA barcodes to track and compare dozens of gold nanoparticle designs in living tumour models, identifying those effective at reaching mitochondria. Two formulations emerged as standout performers, achieving high tumour regression when combined with RNA therapy and photothermal treatment.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.
Researchers Dr Íris Luz Batalha and Dr Maria Shchepinova from the University of Bath have been awarded funding to test new ideas in tackling global health challenges. They will develop precision-targeted therapies for antimicrobial resistance and investigate why treatments for Type 2 diabetes don't work for everyone.
Researchers developed a nasal spray that reversibly reduces brain inflammation, restores cellular power plants, and improves memory. The treatment bypasses the brain's protective shield through intranasal delivery, suppressing chronic inflammation and promoting successful brain aging.
A comprehensive review reveals how phospholipid asymmetry governs EV surface charge, providing a unified framework for classification, functional understanding, and standardization in nanomedicine. The study highlights the importance of membrane lipid composition and surface charge in determining EV function.
Researchers have combined ion pumps with click-to-release chemistry to enable precise electronic control of drug release for a broader range of therapeutics. This technology allows for targeted local therapy with lower doses, reducing side effects.
Researchers at Terasaki Institute for Biomedical Innovation develop a smart contact lens that monitors intraocular pressure in real time and delivers treatment. The technology has shown promising results in preclinical models and aims to improve quality of life for patients with ocular diseases.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
Researchers at the University of Mississippi have developed a new method for delivering cancer-fighting drugs using 3D-printed nanocarriers, which can target specific tumor sites and minimize side effects. This innovative approach has shown promising results in killing cancer cells and reducing the impact of traditional chemotherapy.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
A new study from Oregon State University has found a way to treat both lung cancer and associated muscle-wasting cachexia using lipid nanoparticles. The treatment involves loading the nanoparticles with follistatin messenger RNA, which triggers cells to produce the protein, promoting muscle tissue growth while inhibiting tumors.
Researchers found that clearing intestinal commensal bacteria improves delivery efficiency of various carriers, including polymeric nanoparticles and viral vectors. This study offers a new approach to enhance therapeutic effects in tumor chemotherapy and gene therapy.
A new system generates oxygen, sustaining drug-producing cells for weeks. The device, called HOBIT, integrates engineered cells with oxygen-producing bioelectronics, producing three different biologics in a small animal model.
Early-stage drug development has nearly doubled globally over the past decade, driven by a shift from a US-dominated system to a two-hub structure. This change may have implications for scientific workforce development, investment, and patient access to new therapies.
Researchers have identified and overcome metabolic instability as the key barrier to developing ovalicin, a potent relative of fumagillin. Using chem-bio hybrid synthesis, they created metabolically stable drug candidates that worked in animal models of amebiasis.
A new approach allows oral delivery of drugs previously requiring injection by piggybacking on natural fat absorption pathways. The medication, GlyphAllo, bypasses the liver's security checkpoint and is absorbed through the gut's lymphatic system, allowing it to enter the bloodstream directly.